



OPEN ACCESS

APPROVED BY
Olivier Feron,
Université catholique de Louvain, Belgium

*CORRESPONDENCE
Frontiers Editorial Office,
✉ research.integrity@frontiersin.org

SPECIALTY SECTION
This article was submitted to
Pharmacology of Anti-Cancer Drugs,
a section of the journal
Frontiers in Pharmacology

RECEIVED 21 December 2022
ACCEPTED 21 December 2022
PUBLISHED 05 January 2023

CITATION
Frontiers Editorial Office (2023),
Retraction: Long noncoding RNA FOXD2-
AS1 promotes the malignancy of cervical
cancer by sponging microRNA-760 and
upregulating hepatoma-derived
growth factor.
Front. Pharmacol. 13:1129216.
doi: 10.3389/fphar.2022.1129216

COPYRIGHT
© 2023 Frontiers Editorial Office. This is an
open-access article distributed under the
terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Retraction: Long noncoding RNA FOXD2-AS1 promotes the malignancy of cervical cancer by sponging microRNA-760 and upregulating hepatoma-derived growth factor

Frontiers Editorial Office*

A Retraction of the Original Research Article

[Long noncoding RNA FOXD2-AS1 promotes the malignancy of cervical cancer by sponging microRNA-760 and upregulating hepatoma-derived growth factor Dou X, Zhou Q, Wen M, Xu J, Zhu Y, Zhang S and Xu X \(2020\). *Front. Pharmacol.* 10:1700. doi: 10.3389/fphar.2019.01700](#)

Following publication, concerns were raised regarding the validity of the data in the article. The authors failed to provide the raw data or a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. Given the concerns, and the lack of raw data, the editors no longer have confidence in the findings presented in the article.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors have agreed to the retraction.